Abstract
The inhibitor of apoptosis protein (IAP) family is a group of proteins that are critical regulators of cell survival. They also play roles in cell cycle, cell signaling, and cell migration. The expression of many IAPs is deregulated in acute myeloid leukemia (AML) and other malignant cells and contributes to tumor formation, progression, and maintenance; drug resistance and treatment failure; and poor prognosis. In the last decade, abundant knowledge has been accumulated regarding the structure, expression, regulation, function, and mechanism of action of IAPs, which has led to significant progress in developing strategies to antagonize IAPs. Many candidate compounds have been investigated and tested in the preclinical setting, and some of them have moved to clinical development. This chapter highlightsm current knowledge of the expression and roles of IAPs in AML and discusses current strategies exploiting IAPs as therapeutic targets for AML.
| Original language | English (US) |
|---|---|
| Title of host publication | Targeted Therapy of Acute Myeloid Leukemi |
| Publisher | Springer New York |
| Pages | 151-173 |
| Number of pages | 23 |
| ISBN (Electronic) | 9781493913930 |
| ISBN (Print) | 9781493913923 |
| DOIs | |
| State | Published - Jan 1 2015 |
Keywords
- Aml
- Antisense Oligonucleotide ·
- Apoptosis
- Ciaps
- Smac Mimetics
- Survivin
- Xiap
ASJC Scopus subject areas
- General Medicine
- Pharmacology, Toxicology and Pharmaceutics(all)
- General Biochemistry, Genetics and Molecular Biology
- General Immunology and Microbiology